Stifel lowered the firm’s price target on Verve Therapeutics to $40 from $56 and keeps a Buy rating on the shares. Shares are sharply lower following an earlier VERVE-101 update likely amplified by the small dataset backing the program reminiscent of initial Phase 1b Heart-1 data, the analyst tells investors in a research note. The firm is reluctant to throw in the towel on the program, but is pushing out the drug’s market entry projection by one year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics (NASDAQ:VERV) Plunges on Trial Halt
- Verve Therapeutics Announces Updates on its PCSK9 Program
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics price target lowered to $30 from $32 at Canaccord
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results